When Old Becomes New Again — Creating Value with New Discoveries Based on Known Compounds Webinar

Goodwin will be hosting a webinar titled, “When Old Becomes New Again — Creating Value with New Discoveries Based on Known Compounds.” A recent uptick in activity around new formulations, dosage forms and uses for old compounds inspires this best practices webinar on FDA regulatory pathways, IP protections and market access contracting to maximize potential value. Join us as our panel discusses: FDA regulatory approval pathways, development efficiencies and non-patent exclusivities; IP protection approaches, including formulation and drug and device combination considerations; and the complexities and pitfalls of market access, contracting and pricing. Whether advising companies on regulatory pathways, patent procurement, litigation or market entry and launch, our Late Stage Drug Development team seamlessly advises companies and investors on late stage IP and regulatory matters, with a strategic focus on maximizing the value of drug products by extending exclusivities and enforcing IP rights. Goodwin’s Noelle Dubiansky, Susan Lee, Olivia Uitto, Robert Frederickson, Matt Wetzel and Heath Roosevelt Ingram are featured panelists.